June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Combined Intense Pulsed Light and Low Level Light Therapy Vs. Oral Azithromycin for the treatment of moderate to severe hypersecretory meibomian gland disfunction.
Author Affiliations & Notes
  • José Y. Arteaga Rivera
    Cornea, Instituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, Mexico
  • David Jimenez-Collado
    Cornea, Instituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, Mexico
  • Nicole Macriz-Romero
    Cornea, Instituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, Mexico
  • Arturo Ramírez-Miranda
    Cornea, Instituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, Mexico
  • Carlos Adolfo Müller-Morales
    Cornea, Instituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, Mexico
  • Alejandro Navas
    Cornea, Instituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, Mexico
  • Enrique O Graue-Hernandez
    Cornea, Instituto de Oftalmologia Fundacion Conde de Valenciana IAP, Mexico City, Mexico City, Mexico
  • Footnotes
    Commercial Relationships   José Arteaga Rivera None; David Jimenez-Collado None; Nicole Macriz-Romero None; Arturo Ramírez-Miranda None; Carlos Müller-Morales None; Alejandro Navas None; Enrique Graue-Hernandez None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1966 – A0296. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      José Y. Arteaga Rivera, David Jimenez-Collado, Nicole Macriz-Romero, Arturo Ramírez-Miranda, Carlos Adolfo Müller-Morales, Alejandro Navas, Enrique O Graue-Hernandez; Combined Intense Pulsed Light and Low Level Light Therapy Vs. Oral Azithromycin for the treatment of moderate to severe hypersecretory meibomian gland disfunction.. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1966 – A0296.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare subjective and objective clinical outcomes in patients treated with oral azithromycin or intense pulsed light (IPL) + low level light (LLLT).

Methods : This is a retrospective observational study in 20 patients with moderate to severe hypersecretory meibomian gland disfunction (MGD). Twelve patients were treated with oral azithromycin 1g once a week for 3 weeks, and 11 patients with IPL+LLLT using the Eye-Light® and My Mask® (Espansione Marketing S.p.A, Bologna, Italy) respectively, following the eye-light treatment protocol once a week for 3 weeks. Both groups were reevaluated 1 month after finishing treatment.
Patients with any medication or condition that could modify the ocular surface, macrolide hypersensitivity, pregnant and breastfeeding women were excluded. Variables analyzed were: non–invasive tear break-up time, meibography, tear meniscus height (TMH) and conjunctival redness (OCULUS Keratograph® 5M, Wetzlar, Germany). Uncorrected and corrected visual acuity, tear break-up time (TBUT), Schirmer I test, Oxford scale for fluorescein staining and OSDI scores were also recorded.

Results : Mean patient age was 57.65±10.43 years. All pretreatment variables were similar in both groups (p>0.05). When compared to their baseline measurements the group treated with IPL+LLLT showed statistically significant differences (p<0.05) in TMH (0.34±0.26 to 0.40 ±0.28)), Oxford score (1.32±1.04 to 0.55±0.59), dry eye sensation (3.18±1.60 to 1.55±1.63), eyelid redness (1.82±2.27 to 0.73±1.34), eyelid telangiectasia (1.27±1.00 to 0.27±0.46), eyelid edema (1.09±0.83 to 0.27±0.46), ocular mucus secretion (0.64±0.80 to 0.00) and OSDI scores (44.09±20.29 to 19.09±17.86). The azithromycin group showed significant differences (p<0.05) in TBUT (5.79±4.41to 9.88±10.52), dry eye sensation (3.25±1.48 to 1.75±1.76), eyelid hyperemia (1.41±0.66 to 1.08±0.66) and OSDI scores (36.5±18.68 to 22.25±13.63). When comparing IPL+LLLT group with the azithromycin group, no significant differences were observed.

Conclusions : Both treatments confer improvement in the subjective and objective parameters studied. Despite the fact that no significant differences were observed when comparing both groups, patients treated with IPL+LLLT showed improvement in more variables suggesting that it might be superior for the treatment of hypersecretory MGD.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×